226 related articles for article (PubMed ID: 8980762)
1. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
2. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics.
den Hollander JG; Mouton JW; Verbrugh HA
Antimicrob Agents Chemother; 1998 Apr; 42(4):744-8. PubMed ID: 9559776
[TBL] [Abstract][Full Text] [Related]
3. Characterization of synergy between ofloxacin, ceftazidime, and tobramycin against Pseudomonas aeruginosa.
Madaras-Kelly KJ; Moody J; Larsson A; Baeker Hovde L; Rotschafer JC
Chemotherapy; 1997; 43(2):108-17. PubMed ID: 9084919
[TBL] [Abstract][Full Text] [Related]
4. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
5. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
6. Effect of antibiotic sequence on combination regimens against Pseudomonas aeruginosa in a multiple-dose, in vitro infection model.
Zelenitsky SA; Iacovides H; Harding GK; Ariano RE
Diagn Microbiol Infect Dis; 2004 May; 49(1):67-70. PubMed ID: 15135504
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Gunderson BW; Ibrahim KH; Hovde LB; Fromm TL; Reed MD; Rotschafer JC
Antimicrob Agents Chemother; 2003 Mar; 47(3):905-9. PubMed ID: 12604520
[TBL] [Abstract][Full Text] [Related]
8. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model.
Tessier PR; Nicolau DP; Onyeji CO; Nightingale CH
Chemotherapy; 1999; 45(4):284-95. PubMed ID: 10394012
[TBL] [Abstract][Full Text] [Related]
10. In vitro comparison of cefpirome and four other beta-lactam antibiotics alone and in combination with tobramycin against clinical isolates of Pseudomonas aeruginosa.
Cabezudo I; Pfaller M; Bale M; Wenzel R
Diagn Microbiol Infect Dis; 1989; 12(4):337-41. PubMed ID: 2512048
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.
Cappelletty DM
Antimicrob Agents Chemother; 1999 Jan; 43(1):129-33. PubMed ID: 9869577
[TBL] [Abstract][Full Text] [Related]
12. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
Chan EL; Zabransky RJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.
Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB
J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model.
Zhuang L; Sy SK; Xia H; Singh RP; Mulder MB; Liu C; Derendorf H
Int J Antimicrob Agents; 2015 Feb; 45(2):151-60. PubMed ID: 25465523
[TBL] [Abstract][Full Text] [Related]
15. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
Dundar D; Otkun M
Yonsei Med J; 2010 Jan; 51(1):111-6. PubMed ID: 20046523
[TBL] [Abstract][Full Text] [Related]
16. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
Petit JC; Richard G; Burghoffer B; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 1995 Nov; 39(11):2503-10. PubMed ID: 8585734
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of the activity of cephalosporins against Pseudomonas aeruginosa.
Bauernfeind A
J Antimicrob Chemother; 1981 Sep; 8 Suppl B():111-7. PubMed ID: 19810172
[TBL] [Abstract][Full Text] [Related]
19. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
20. Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 Apr; 42(4):953-5. PubMed ID: 9559819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
